Millipore Sigma Vibrant Logo

528208 Plasminogen Activator Inhibitor-1, Mutant, Human, Recombinant - Calbiochem

The Plasminogen Activator Inhibitor-1, Mutant, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Plasminogen Activator Inhibitor-1, Mutant, Human, Recombinant - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: PAI-1, Mutant

Primary Target: Plasminogen Activator
View This Product on Sigma-Aldrich
528208
  
価格を検索中…
価格が見つかりません
Minimum Quantity needs to be mulitiple of
Maximum Quantity is
弊社照会 詳細を表示　
値引
()
 
—
弊社照会
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

       

      お問合せください

      概要

      Replacement Information
      Description
      OverviewHighly purified preparation of an altered form of human PAI-1 containing four mutated amino acids. Mutant PAI-1 is virtually unable to go latent and is stable at elevated temperature and pH for extended periods of time (t½ = 145 hours at 37°C, pH 7.4). Inhibits uPA (Ki = 5.1 x 106 M-1 sec-1) and tPA (Ki = 7.9 x 105 M-1 sec-1).
      Catalogue Number528208
      Brand Family Calbiochem®
      SynonymsPAI-1, Mutant
      References
      ReferencesBerkenpas, M.B., et al. 1995. EMBO J. 14, 2969.
      Product Information
      ATP CompetitiveN
      FormLiquid
      FormulationIn 100 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
      ReversibleN
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetPlasminogen Activator
      Primary Target K<sub>i</sub>5.1 x 106 M-1 sec-1, 7.9 x 105 M-1 sec-1 against uPA and tPA, respectively
      Purity≥95% by SDS-PAGE assay
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      528208 0

      Documentation

      Plasminogen Activator Inhibitor-1, Mutant, Human, Recombinant - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      Plasminogen Activator Inhibitor-1, Mutant, Human, Recombinant - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      528208

      参考資料

      参考資料の概要
      Berkenpas, M.B., et al. 1995. EMBO J. 14, 2969.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision22-July-2024 JSW
      SynonymsPAI-1, Mutant
      DescriptionHighly purified preparation of an altered form of human PAI-1 containing four mutated amino acids. Mutant PAI-1 is virtually unable to go latent and is stable at elevated temperature and pH for extended periods of time (t½ = 145 h at 37°C, pH 7.4). Inhibits uPA (Ki = 5.1 x 106 M-1sec-1) and tPA (Ki = 7.9 x 105 M-1sec-1).
      FormLiquid
      FormulationIn 100 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
      Concentration Label Please refer to vial label for lot-specific concentration
      Purity≥95% by SDS-PAGE assay
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesBerkenpas, M.B., et al. 1995. EMBO J. 14, 2969.